Medical/Pharmaceuticals
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
2021-10-15 12:44
2514
International Biopharma Industry Week Shanghai 2021 Opens
SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- On October 11, the International Biopharma Industry Week Shanghai 2021, under the guidance of the Shanghai Biomedical Industry Development Leading Group, the inaugural International Biopharma Industry Week Shanghai (IBIWS) is co-hosted by Shanghai Biomedica...
2021-10-15 12:22
4658
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx
SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Abbisko (SEHK:2256), a clinical-stage biopharmaceutical company, listed on the main board of the Hong Kong Stock Exchange onOctober 13. The issue price isHK$ 12.46 per share, representing a market cap of HK$ 8.753 ...
2021-10-15 12:00
4687
Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results.
* One-shot Sputnik Light is the first component of the Sputnik V vaccine, the world's first registered vaccine against coronavirus. Sputnik V pioneered the heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus seroty...
2021-10-15 05:26
2635
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin ...
2021-10-14 20:46
4035
Roan Holdings Group Announces Agreement to Set Up Joint Venture to Expand in Consumer Health Services Market
BEIJING and HANGZHOU, China, Oct. 14, 2021 /PRNewswire/ -- Roan Holdings Group Co., Ltd. ("Roan" or the "Company") (OTC Pink: RAHGF and RONWF), a provider of diversified solutions in financial, insurance and healthcare related products and management services, today announced that the Company's s...
2021-10-14 20:00
2899
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with Its AI Immunology Platforms
The company's PIONEER™, EDEN™, and RAVEN™ platforms mimic the human immune system to simplify the drug development process for a range of diseases LONDON, Oct. 14, 2021 /PRNewswire/ -- Based on its recent analysis of the European AI-enabled drug discovery market,Frost & Sullivan recognizes Evaxio...
2021-10-14 19:30
2293
BioAgilytix Closes Acquisition of Australia-based 360biolabs®
Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 /...
2021-10-14 19:00
2093
BioAgilytix Closes Acquisition of Australia-based 360biolabs®
Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 ...
2021-10-14 19:00
2286
21 Swiss Startups to take the Stage at China's Hottest Tech Expos
SHANGHAI, Oct. 14, 2021 /PRNewswire/ -- 21 Swiss startups will be joining the primely-located SwissTech Pavilions at China Hi-Tech Fair fromNovember 17 - 21, 2021 in Shenzhen, and Tech G Shanghai International Consumer Electronics Show fromJanuary 13 - 15, 2022 in Shanghai. The world-class Swiss...
2021-10-14 16:18
1501
A China-developed COVID-19 vaccine is conducting clinical trial in Philippines
CHENGDU, China, Oct. 14, 2021 /PRNewswire/ -- Philippines is currently conducting, along with other countries includingIndonesia, Kenya, and Mexico, a Phase III clinical trial of Recombinant COVID-19 Vaccine (Sf9 cells) produced by WestVac Biopharma Co., LTD and National Key Laboratory of Bioth...
2021-10-14 12:58
2643
Restart-A-Heart Day - Targets Aussie Women
MELBOURNE, Australia, Oct. 14, 2021 /PRNewswire/ -- Recent studies reveal women
are 27% less likely to receive CPR in a public setting compared to men.
2021-10-14 09:15
2862
New Information from NCCN on Most Common Type of Cancer; Diagnosed in Millions Every Year
New NCCN Guidelines for Patients: Basal Cell Skin Cancer empowers patients and caregivers with knowledge about this widespread, preventable, and easily-cured cancer plus the rare subset that requires more aggressive treatment. PLYMOUTH MEETING, Pa., Oct. 13, 2021 /PRNewswire/ -- The National Com...
2021-10-13 22:07
3954
One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows
* The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalizations. * Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decli...
2021-10-13 20:30
5765
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will...
2021-10-13 20:30
4365
Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week inShanghai (IBIWS) running from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote speech at the "2021 Future ...
2021-10-13 20:20
4561
Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt
JIUQUAN, China, Oct. 13, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "...
2021-10-13 20:00
2765
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...
2021-10-13 20:00
1970
Shanghai, industry partners to co-build world-class biopharma industry cluster
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...
2021-10-13 19:43
1996
The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...
2021-10-13 15:47
1760
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
19959
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
19833
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
17794
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
13441